(S)-1-benzyl-2-oxo-3-(tert-butoxycarbonylamino)-azepine | 380629-65-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-1-benzyl-2-oxo-3-(tert-butoxycarbonylamino)-azepine
• 英文别名: (S)-tert-butyl 1-benzyl-2-oxoazepan-3-ylcarbamate；[(3S)-hexahydro-2-oxo-1-(phenylmethyl)-1H-azepin-3-yl]-carbamic acid 1,1-dimethylethyl ester；1,1-dimethylethyl [(3S)-hexahydro-1-phenylmethyl-2-oxo-1H-azepin-3-yl]carbamate；tert-butyl N-[(3S)-1-benzyl-2-oxoazepan-3-yl]carbamate
• CAS: 380629-65-2
• 化学式: C₁₈H₂₆N₂O₃
• 分子量: 318.416
• InChiKey: FXMZBKOAALYZDU-HNNXBMFYSA-N

物化性质

• 沸点：
  501.5±49.0 °C(Predicted)
• 密度：
  1.12±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  58.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (S)-1-benzyl-2-oxo-3-(tert-butoxycarbonylamino)-azepine 在 N-甲基吗啉 、 盐酸 、 甲酸 、 硼烷四氢呋喃络合物 、 palladium 10% on activated carbon 、 三乙酰氧基硼氢化钠 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 13.67h， 生成 tert-butyl (S)-1-((S)-1-cyclohexyl-2-oxo-2-((S)-1-phenethylazepan-3-ylamino)ethylamino)-1-oxopropan-2-yl(methyl)carbamate
  参考文献：
  名称：

  Discovery of aminopiperidine-based Smac mimetics as IAP antagonists

  摘要：

  A series of structurally unique Smac mimetics that act as antagonists of inhibitor of apoptosis proteins (IAPs) has been discovered. While most previously described Smac mimetics contain the proline ring (or a similar cyclic motif) found in Smac, a key feature of the compounds described herein is that this ring has been removed. Despite this, compounds in this series potently bind to cIAP1 and elicit the expected phenotype of cIAP1 inhibition in cancer cells. Marked selectivity for cIAP1 over XIAP is observed for these compounds, which is attributed to a slight difference in the binding groove between the two proteins and the resulting steric interactions with the inhibitors. XIAP binding can be improved by constraining the inhibitor so that these unfavorable steric interactions are minimized. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.12.109
• 作为产物：
  描述：

  tert-butyl (S)-(4,4-dimethyl-2-oxoazepan-3-yl)carbamate 在 RuCl2(1,3-dimesityl-imidazolidin-2-yl)(PCy3)(=CHPh) 、 palladium on activated charcoal 、 氢气 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 18.0h， 生成 (S)-1-benzyl-2-oxo-3-(tert-butoxycarbonylamino)-azepine
  参考文献：
  名称：

  基于闭环复分解的纤毛酰胺A和B的全合成及其结构确认

  摘要：

  已经描述了基于保护基的基于闭环复分解的方法来完全合成纤毛酰胺A和B的修饰结构。当前的合成策略利用氨基酸作为起始材料来引入两个立体异构中心。但是，要使用非消旋试剂（EDC·HCl，HATU / NMM）；酰胺偶联的合成和格鲁布斯的第二代己内酰胺环合成催化剂使本方法更方便地获得关于绝对立体化学的正确结论。因此，基于与林德斯利报道的数据相似的旋光度值，该合成进一步支持纤毛酰胺A和B的实际立体化学为（R，R）。

  DOI：

  10.1016/j.tetlet.2016.03.017

文献信息

• [EN] SUBSTITUTED ADIPIC ACID AMIDES AND USES THEREOF<br/>[FR] AMIDES DE L'ACIDE ADIPIQUE SUBSTITUÉS ET LEURS UTILISATIONS
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2012125622A1

  公开（公告）日：2012-09-20

  The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, wherein A is a five to eight membered monocyclic or a nine to twelve membered bicyclic heterocyclic ring, as further defined herein; Y is S, CH2, or CH; Z is CH or N; R7 and R9 are hydrogen or (C1-C6)alkyl; R2 is (C1 C6)alkoxy, OH, CN, (C1-C6)alkyl, halogen, or CF3; r and s are 0, 1, or 2; and R1 and R3 are as further defined herein. These compounds are agonists, partial agonists and/or modulators of the NPY4 receptor and may be used for the treatment and prophylaxis of obesity, food intake, and other diseases and conditions modulated by the NPY4 receptor.

  本发明提供了式（I）的化合物或其药学上可接受的盐，其中A是一个五至八元的单环或一个九至十二元的双环杂环环，如本文所进一步定义；Y是S、CH2或CH；Z是CH或N；R7和R9是氢或（C1-C6）烷基；R2是（C1-C6）烷氧基、羟基、氰基、（C1-C6）烷基、卤素或三氟甲基；r和s为0、1或2；R1和R3如本文所进一步定义。这些化合物是NPY4受体的激动剂、部分激动剂和/或调节剂，可用于治疗和预防肥胖、食物摄入和其他由NPY4受体调节的疾病和症状。
• Lactam inhibitors of factor Xa and method
  申请人：——

  公开号：US20020025957A1

  公开（公告）日：2002-02-28

  Lactam inhibitors are provided which have the structure 1 including pharmaceutically acceptable salts thereof and all stereoisomers thereof, and prodrug esters thereof, wherein n is 1 to 5; and and R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 10a , 10 11 and R 12 are as defined herein. These compounds are inhibitors of Factor Xa and thus are useful as anticoagulants. A method for treating cardiovascular diseases associated with thromboses is also provided.

  提供了具有以下结构的内酰胺抑制剂 1 ，包括其药用可接受的盐及其所有立体异构体，以及其前药酯，其中n为1至5；和 和R 1 ，R 2 ，R 3 ，R 4 ，R 5 ，R 6 ，R 7 ，R 8 ，R 9 ，R 10 ，R 10a ，10 11 和R 12 如本文所定义。这些化合物是因子Xa的抑制剂，因此可用作抗凝剂。还提供了一种用于治疗与血栓相关的心血管疾病的方法。
• Stereochemical Diversity in Asymmetric Cyclization via Memory of Chirality
  作者：Takeo Kawabata、Seiji Matsuda、Shimpei Kawakami、Daiki Monguchi、Katsuhiko Moriyama

  DOI：10.1021/ja0670761

  日期：2006.12.1

  potassium amide bases in DMF, cyclization proceeds with retention of configuration, while inversion of configuration was observed with lithium amide bases in THF. Chirality of the parent amino acids was preserved during enolate formation and cyclization to give aza-cyclic amino acids in up to 98% ee with retention of configuration or inversion of configuration, depending on the reaction conditions. Thus, both

  已开发出 N-Boc-N-ω-溴烷基-α-氨基酸衍生物的对映发散不对称环化。在 DMF 中使用氨基钾碱时，环化在构型保留的情况下进行，而在 THF 中使用氨基化锂碱时观察到构型反转。在烯醇化物形成和环化过程中保留了母体氨基酸的手性，以产生高达 98% ee 的氮杂环氨基酸，并保留构型或反转构型，这取决于反应条件。因此，具有四取代立体中心的环状氨基酸的两种对映异构体均以高对映异构纯度从容易获得的l-α-氨基酸制备。该协议也适用于α-氨基酸衍生物的螺环化和分子内共轭添加，
• SUBSTITUTED ADIPIC ACID AMIDES AND USES THEREOF
  申请人：Sun Chongqing

  公开号：US20130345123A1

  公开（公告）日：2013-12-26

  The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, wherein A is a five to eight membered monocyclic or a nine to twelve membered bicyclic heterocyclic ring, as further defined herein; Y is S, CH 2 , or CH; Z is CH or N; R 7 and R 9 are hydrogen or (C 1 -C 6 )alkyl; R 2 is (C 1 -C 6 )alkoxy, OH, CN, (C 1 -C 6 )alkyl, halogen, or CF 3 ; r and s are 0, 1, or 2; and R 1 and R 3 are as further defined herein. These compounds are agonists, partial agonists and/or modulators of the NPY4 receptor and may be used for the treatment and prophylaxis of obesity, food intake, and other diseases and conditions modulated by the NPY4 receptor.

  本发明提供了式（I）的化合物或其药学上可接受的盐，其中A是进一步定义的五至八元杂环或九至十二元双环杂环；Y是S，CH2或CH；Z是CH或N；R7和R9是氢或（C1-C6）烷基；R2是（C1-C6）烷氧基，羟基，氰基，（C1-C6）烷基，卤素或CF3；r和s为0、1或2；而R1和R3的定义进一步如下。这些化合物是NPY4受体的激动剂、部分激动剂和/或调节剂，可用于治疗和预防肥胖、食物摄入和其他受NPY4受体调节的疾病和状况。
• Substituted adipic acid amides and uses thereof
  申请人：Sun Chongqing

  公开号：US09346852B2

  公开（公告）日：2016-05-24

  The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, wherein A is a five to eight membered monocyclic or a nine to twelve membered bicyclic heterocyclic ring, as further defined herein; Y is S, CH2, or CH; Z is CH or N; R7 and R9 are hydrogen or (C1-C6)alkyl; R2 is (C1-C6)alkoxy, OH, CN, (C1-C6)alkyl, halogen, or CF3; r and s are 0, 1, or 2; and R1 and R3 are as further defined herein. These compounds are agonists, partial agonists and/or modulators of the NPY4 receptor and may be used for the treatment and prophylaxis of obesity, food intake, and other diseases and conditions modulated by the NPY4 receptor.

  本发明提供了公式（I）的化合物或其药学上可接受的盐，其中A是进一步定义的五至八元的单环或九至十二元的双环杂环环，Y是S，CH2或CH; Z是CH或N; R7和R9是氢或（C1-C6）烷基; R2是（C1-C6）烷氧基，羟基，氰基，（C1-C6）烷基，卤素或CF3; r和s为0,1或2; R1和R3如进一步定义。这些化合物是NPY4受体的激动剂，部分激动剂和/或调节剂，可用于治疗和预防肥胖，食物摄入和其他受NPY4受体调节的疾病和状况。